FGFR3 and urinary bladder carcinoma: Preclinical studies have demonstrated that human bladder cancer cell lines with FGFR3 mutations and fusions are sensitive to FGFR inhibitors such as BGJ398 (Infigratinib, Novartis), PD173074 (Pfizer) and erdafitinib (Balversa, Janssen) [17, 19–22], thereby forming the basis for clinical trials of FGFR inhibitors in patients with metastatic urothelial cancer.